The in vivo mechanism(s) by which these MHC class I-restricted CD4+ T cells mediate anti-tumor effects could be further investigated by in vivo blockade of IFN-γ, TNF-α or IL-2, or by using IFN-γR or TNF-αR knockdown cancer cells. The gene discussed is CD4; the disease is cancer.